Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.

European journal of cancer (Oxford, England : 1990) - 26 Aug 2026

Pobel Cedric, Badreddine Hassan, Smolenschi Cristina, Boileve Alice, Ducreux Michel, Friboulet Luc, Bahledal Rastislav, Gazzah Anas, Beshiri Kristi, Porte Marie, Ben-Ammar Imen, Audisio Marie-Anne, Ouali Kaissa, Bani Mohamed, Loriot Yohann, Vasseur Damien, Gelli Maximilliano, Massard Christophe, Facchinetti Francesco, Hollebecque Antoine

Abstract excerpt

BACKGROUND: Fibroblast growth factor receptor (FGFR) alterations including mutations, fusions and amplifications, are known oncogenic drivers. FGFR tyrosine kinase inhibitors (FGFRi) have demonstrated clinical activity in patients with FGFR3-driven urothelial carcinoma and FGFR2-driven cholangiocarcinoma. This study aims to describe outcomes with FGFRi according to alteration and tumor type. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to FGFR2 gene

Share to FGFR3 gene

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Receptors, Fibroblast Growth Factor

Share to Treatment Outcome

Source

Identifiers

PMID: 42330567
DOI: 10.1016/j.ejca.2026.116900

Genes

FGFR2
FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.PMID 42330567Read ↗

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Semantic proximity Read ↗

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity Read ↗

Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterationsSemantic proximity Read ↗

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial.Semantic proximity Read ↗

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Semantic proximity Read ↗

FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma.Semantic proximity Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Semantic proximity Read ↗

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Semantic proximity Read ↗

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Semantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

Rapid Autopsy Multi-Omic Analysis Identifies Divergent Evolutionary Trajectories and DNA Damage Resistance Mechanisms in FGFR2-Driven CholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.